Biogen Inc. announced plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation plan in Massachusetts. The move centralizes Biogen’s presence in Kendall Square, integrating Biogen’s research and development and technical operations teams alongside its global and North American commercial organizations into a co-located innovation hub. Scheduled to open when Biogen celebrates its 50th anniversary in 2028, the new state-of-the-art facility will commemorate five decades of excellence in scientific discovery, clinical development, and delivering innovative new treatments.
“Nearly 50 years after first putting down roots in Kendall Square, Biogen is embarking on a new chapter in the very heart of the community that has shaped our success,” said Christopher A. Viehbacher, President and Chief Executive Officer at Biogen. “Our new space will support the advancement of our pipeline of breakthrough medicines by bringing our employees together and fostering collaboration with leading scientific minds, key partners, and top talent.”
“Biogen has been a foundational presence in the Massachusetts life science ecosystem for close to half a century, and we are thrilled to see them begin a new era in our state,” said Maura Healey, Governor of Massachusetts. “This milestone is an example of why Massachusetts remains the center for long-term growth and opportunity in the life sciences. Our administration continues to make investments in the sector in order to help create more companies and jobs that lead to innovative new treatments for patients.”
“It’s fitting that Biogen — a company with such close ties to people at MIT — will make Kendall Common’s first building its new home,” said Sally Kornbluth, President of MIT. “The motto of Kendall Square might as well be 'talent in proximity' and Biogen's decision to intensify its presence here promises great things for the whole ecosystem. To achieve this milestone on the occasion of the company’s 50th anniversary is especially meaningful. We are grateful to Chris Viehbacher, president and chief executive officer of Biogen, for his keen vision of the future and his ongoing commitment to Cambridge and Kendall Square.”
“Massachusetts is the global leader in biotechnology because Biogen pioneered a scientific revolution decades ago. The decision by Biogen today to develop a new hub here goes to the very core of what makes this ecosystem great: collaboration, talent, and institutions,” said Kendalle Burlin O’Connell, Chief Executive Officer & President of MassBio. “This is the place patients around the world look to for lifesaving medicines and with this new facility, Biogen is breaking ground on the future of biomedical innovation and solidifying the Commonwealth’s dominance in healthcare.”
Comments powered by CComment